Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by As03adjuvanted H1n1 Pandemic Influenza Vaccine

Research Leaders

10 sponsors active, led by China Academy of Chinese Medical Sciences

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 6 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

6Total
Not Applicable (1)
Phase 1 (2)
Phase 3 (2)
Phase 4 (1)

Trial Status

Completed5
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 5 completed trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01063608Phase 4CompletedPrimary

Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.

NCT00973895Phase 1CompletedPrimary

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

NCT00989404Phase 1CompletedPrimary

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

NCT01053143Phase 3Completed

Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India

NCT01053533Not ApplicableUnknownPrimary

A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza

NCT01016548Phase 3Completed

Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy

Showing all 6 trials

Research Network

Common Treatments

  • As03adjuvanted H1n1 Pandemic Influenza Vaccine1
  • Chinese Herbal Medicines Plus Western Therapy1
  • Antih1n1v Vaccine1
  • Vrcfludna05700vp1
  • Western Therapy1

Active Sponsors

  • China Academy of Chinese Medical Sciences1
  • GSK1
  • Institut National de la Santé Et de la Recherche Médicale, France1
  • Princess Margaret Hospital, Canada1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

Related Conditions

  • Pandemic Influenza1
  • Influenza1
  • Lymphoma1
  • Novel Swineorigin1
  • Multiple Myeloma1

Activity Timeline